SEC Form 4 · accession 0001209191-17-040971
Insight Molecular Diagnostics Inc. · IMDX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew Arno
Director
Period of report
Jun 15, 2017
Accepted (ET)
Jun 19, 2017 · 9:09 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001642380
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common StockF1,F2 | $5.10 | Jun 15, 2017 | A | 6,520 | A | — | Jun 14, 2027 | Common Stock | 6,520 | 6,520 | D |
| Option to Purchase Common StockF2 | $5.10 | Jun 15, 2017 | A | 20,000 | A | — | Jun 14, 2027 | Common Stock | 20,000 | 20,000 | D |
Explanation of responses
- F1Options are granted to directors annually. These options are a "transitional grant" reflecting the change in the date of the annual grant from February to the date of the annual meeting of shareholders. The options are 32.60% of the annual grant for the 119-day gap between February 16, 2017, one year from the last annual grant, and June 15, 2017, date of the full annual grant for 2017-2018.
- F2Will become exercisable in four equal installments on September 30, 2017, December 31, 2017, March 31, 2018, and one day before the Company's next annual meeting of shareholders, based upon continued service on the board of directors from the date of grant on June 15, 2017.